研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co.,Ltd.[2]First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China,650000[3]The Second People's Hospital of Heifei Hefei,Anhui,China,230000[4]Ma'anshan People's Hospital Ma'anshan,Anhui,China,243000[5]Yijishan Hospital of Wannan Medical College Wuhu,Anhui,China,241000[6]The First Affiliated Hospital of Chongqing Medical University Chongqing,Chongqing,China,400000[7]The Ninth People's Hospital of Chongqing Chongqing,Chongqing,China,400000[8]The Second Affiliated Hospital of Chongqing Medical University Chongqing,Chongqing,China,400000[9]Affiliated Hospital of Guangdong Medical University Zhanjiang,Guangdong,China,524000[10]Liuzhou People's Hospital Liuzhou,Guangxi,China,545000
研究目的：
Liraglutide injection is a glucagon-like peptide-1 (GLP-1) analogue that activates the cyclic adenosine monophosphate (cAMP) and mitogen-activated protein kinase (MAPK) pathway by binding to the GLP-1 receptor (GLP-1R),thus,it has physiological effects such as glucose-dependent insulin synthesis and secretion, inhibition of β-cell apoptosis, promotion of β-cell proliferation and regeneration, inhibition of glucagon secretion, reduction of food intake, delay of gastric emptying, enhancement of glucose utilization in peripheral tissues and reduction of glycogen output. Liraglutide injection,developed and marketed as Victoza® by Novo Nordisk,is indicated for the treatment of patients with type 2 diabetes and was approved by the U.S. Food and Drug Administration in 2010.This 26-week trial compares the effectivity on glycaemic control,safety and immunogenicity of liraglutide injection and Victoza® in patients with type 2 diabetes inadequately controlled by oral metformin alone.
